Molecular virology of hepatitis B virus

Seminars in Liver Disease

Volumn 24, Issue SUPPL. 1, 2004, Pages 3-10

  Locarnini, Stephen ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

Covalently closed circular DNA; Drug resistance; Reverse transcription; Vaccine escape; Viral mutants

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B VACCINE; LAMIVUDINE; VIRUS DNA;

CONFERENCE PAPER; DISEASE COURSE; ESCAPE BEHAVIOR; HEPATITIS B; HEPATITIS B VIRUS; HOST RESISTANCE; HUMAN; IMMUNITY; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; LIFE CYCLE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; VIROLOGY; VIRUS GENOME; VIRUS LOAD; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION;

EID: 2942534508     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-828672     Document Type: Conference Paper

References (43)

1. Guidotti LG, Rochford R, Chung J, et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999;284:825-829
2. Nayersina R, Fowler P, Guilhot S, et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 1993;150:4659-4671
3. Rehermann B, Fowler P, Sidney J, et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995;181:1047-1058
4. Penna A, Del Prete G, Cavalli A, et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 1997;25: 1022-1027
5. Webster GJ, Reignat S, Maini MK, et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 2000;32:1117-1124
6. Ferrari C, Penna A, Giuberti T, et al. Intrahepatic, nudeocapsid antigen-specific T cells in chronic active hepatitis B. J Immunol 1987;139:2050-2058
7. Barnaba V, Franco A, Alberti A, et al. Recognition of hepatitis B virus envelope proteins by liver-infiltrating T lymphocytes in chronic HBV infection. J Immunol 1989;143: 2650-2655
8. Lohr HF, Gerken G, Schlicht HJ, Meryer zum Buschenfelde KH, Fleischer B. Low frequency of cytotoxic liver-infiltrating T lymphocytes specific for endogenous processed surface and core proteins in chronic hepatitis B. J Infect Dis 1993;168: 1133-1139
9. Jung M, Pape G. Immunology of hepatitis B infection. Lancet Infect Dis 2002;2:43-50
10. Guidotti LG, Chisari FV. Cytokine-mediated control of viral infections. Virology 2000;273:221-227
11. Ganem D, Schneider R. Hepadnaviridae: the viruses and their replication. In: Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott-Raven; 2001:2923-2970
12. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994;198:489-503
13. Stuyver L, De Gendt S, Van Geyt C, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000;81:67-74
14. Kann M, Bischof A, Gerlich WH. In vitro model for the nuclear transport of the hepadnavirus genome. J Virol 1997; 71:1310-1316
15. Ganem D. Hepadnaviridae and their replication. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology, 3rd ed. Philadelphia: Raven; 1996:2703-2737
16. Tavis J. The replication strategy of the Hepadanaviruses. Viral Hepatitis Reviews 1996;2:205-218
17. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982;29:403-415
18. Okamoto H, Imai M, Kametani M, et al. Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission. Jpn J Exp Med 1987;57:231-236
19. Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary, structure of the pre-genome encapsidation signal. Proc Natl Acad Sci USA 1994;91:4077-4081
20. Hunt CM, McGill JM, Allen MI, et al. Clinical relevance of hepatitis B viral mutations. Hepatology 2000;31:1037-1044
21. Gunther S, Fischer L, Pult I, et al. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999;52:25-137
22. Akarca US, Lok AS. Naturally occurring hepatitis B virus core gene mutations. Hepatology 1995;22:50-60
23. Carman WF, Zanetti AR, Karayiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990;336:325-329
24. Carman WF, Trautwein C, van Deursen FJ, et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996;24:489-493
25. Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001;33:751-757
26. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with development of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125:292-297
27. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36: 687-696
28. Leung N. Clinical experience with lamivudine. Semin Liver Dis 2002;22(Suppl 1):15-21
29. Delaney WE IV, Locarnini S, Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antivir Chem Chemother 2001;12:1-35
30. Ogata N, Fujii K, Takigawa S, et al. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol 1999;59:270-276
31. Bock C, Tillmann H, Torresi J, et al. HBV polymerase mutants with enhanced replication selected during lamivudine therapy result in sudden onset of liver failure. Gastroenterology 2002;122:264-273
32. Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-851
33. Papatheodoridis GV, Dimou E, Laras A, et al. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002;36:219-226
34. Chen R, Edwards R, Shaw T, et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003;37: 27-35
35. Wang JH, Lu SN, Lee CM, et al. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scand J Gastroenterol 2002;37:366-369
36. Liaw Y-F, Chien R-N, Yeh C-T, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30:567-572
37. De Man RA, Bartholomeusz A, Niesters HGM, et al. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B virus: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J Hepatol 1998;29:669-675
38. Soriano V. Hepatitis B virus infection despite receiving lamivudine in one HIV-infected person. HIV Clin Trials 2003;4:77-78
39. Ayres A, Bartholomeusz A, Lau GK, et al. Lamivudine and famciclovir resistant hepatitis B virus associated with fatal hepatic failure. J Clin Virol 2003;27:111-116
40. Thibault V, Aubron-Olivier C, Agut H, et al. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 2002;16:131-133
41. Shaw T, Locarnini S. Combination chemotherapy for hepatitis B virus: the path forward? Drugs 2000;60:517-531
42. Locarnini S, Birch C. Antiviral chemotherapy for chronic hepatitis B infection: Lessons learned from treating HIV infected patients. J Hepatol 1999;30:536-550
43. Lewin SR, Ribeiro RM, Walter T, et al. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 2001;34:1012-1020